BioNTech SE (BNTX)

How it makes money

Most revenue comes from BioNTech's share of Comirnaty and Paxlovid economics under its Pfizer collaboration, which moves with global COVID-19 vaccination demand rather than with any sales effort of BioNTech's own, and has been shrinking as pandemic-era demand fades. On top of that, BioNTech recognizes collaboration revenue tied to milestones under its Bristol Myers Squibb oncology partnership, income from a German government pandemic-preparedness manufacturing contract, and smaller service revenues; none of these yet come from a BioNTech-branded oncology product on the market.

BioNTech's mRNA manufacturing know-how and patent estate, built and proven at unprecedented speed and scale during the pandemic, are real technical assets that a new entrant cannot easily copy. But the moat is narrow because it has not yet translated into a second commercial franchise: today's revenue still depends heavily on a declining, Pfizer-shared product, and the oncology pipeline that is meant to succeed it remains unapproved.

Demand for COVID-19 vaccination does not track the economic cycle, but it has been declining structurally as the acute phase of the pandemic recedes and is now closer to a seasonal, government-purchase-driven pattern. The future oncology business, meanwhile, has no revenue history yet and its trajectory will depend on clinical trial results and regulatory approvals rather than on consumer spending patterns.

Key risks

• Dependence on the Pfizer collaboration — Most revenue still comes from BioNTech's profit-sharing arrangement with Pfizer for Comirnaty and Paxlovid; declining COVID-19 vaccine demand or a change in that partnership would directly reduce the company's main income source.
• Unproven, capital-intensive oncology pipeline — BioNTech continues to invest heavily in research and late-stage development, including large global trials, for cancer candidates that are not yet approved, so future growth depends on clinical and regulatory outcomes that are inherently uncertain.
• Reliance on the Bristol Myers Squibb partnership — A meaningful part of BioNTech's near-term oncology revenue and pipeline progress is tied to its collaboration with Bristol Myers Squibb; a change in that partner's commitment or strategy would affect both funding and commercialization plans.
• Dependence on government contracts — Part of BioNTech's revenue comes from a German government pandemic-preparedness manufacturing contract; non-renewal or a change in government priorities would remove a source of income that is not tied to product sales.

BioNTech does not disclose a single revenue-concentration percentage, but the Pfizer collaboration for Comirnaty and Paxlovid remains by far its largest counterparty relationship and drives the majority of current revenue.